U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07641855) titled 'A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer' on June 08.
Brief Summary: This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Castration-resistant Prostate Cancer
Intervention:
DRUG: BL-B01D1
Administration by intravenous infusion for a cycle of 3 weeks.
DRUG: Abiraterone
Oral administration for a cycle of 3 weeks.
DRUG: Olaparib
Oral administration for a cycle of 3 weeks.
Recruitment Status: NO...